DNA Biomed Solns Asset Resilience Ratio

Latest as of June 2021: 3.82%

DNA Biomed Solns asset resilience ratio. DNA Biomed Solns (DNA) has an Asset Resilience Ratio of 3.82% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DNA Biomed Solns balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

ILA2.35 Million

≈ $6.29K USD Cash + Short-term Investments

Total Assets

ILA61.52 Million

≈ $164.92K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of DNA Biomed Solns (2011–2019)

Asset resilience ratio of DNA Biomed Solns from 2011 to 2019. This chart shows how DNA Biomed Solns's Asset Resilience Ratio has changed over time. See DNA free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down DNA Biomed Solns's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of DNA Biomed Solns.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	ILA0.00	0%
Short-term Investments	ILA2.35 Million	3.82%
Total Liquid Assets	ILA2.35 Million	3.82%

Asset Resilience Insights

Limited Liquidity: DNA Biomed Solns maintains only 3.82% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

DNA Biomed Solns Industry Peers by Asset Resilience Ratio

Compare DNA Biomed Solns's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Shanghai Medicilon Inc SHG:688202	Biotechnology	6.69%
Blue Jet Healthcare Limited NSE:BLUEJET	Biotechnology	13.81%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.76%
Shenzhen Weiguang Biological Products Co Ltd SHE:002880	Biotechnology	5.52%

DNA Biomed Solns Asset Resilience Ratio by Year (2011–2019)

DNA Biomed Solns asset resilience ratio by year from 2011 to 2019. The table below shows the annual Asset Resilience Ratio data for DNA Biomed Solns.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2019-12-31	7.62%	ILA2.80 Million ≈ $7.51K	ILA36.73 Million ≈ $98.49K	-3.20pp
2016-12-31	10.82%	ILA4.13 Million ≈ $11.08K	ILA38.17 Million ≈ $102.34K	-5.29pp
2013-12-31	16.12%	ILA3.33 Million ≈ $8.94K	ILA20.68 Million ≈ $55.45K	+2.62pp
2012-12-31	13.50%	ILA2.86 Million ≈ $7.67K	ILA21.20 Million ≈ $56.84K	+7.30pp
2011-12-31	6.20%	ILA1.04 Million ≈ $2.80K	ILA16.82 Million ≈ $45.10K	--

pp = percentage points

About DNA Biomed Solns

TA:DNA Israel Biotechnology

Market Cap

$38.30 Million

ILA14.29 Billion ILA

Market Cap Rank

#22691 Global

#314 in Israel

Share Price

ILA116.00

Change (1 day)

+1.93%

52-Week Range

ILA86.00 - ILA147.50

All Time High

ILA1900.80